cas 80343-16-4|| where to buy 1-methyl-3-(trifluoromethyl)-1H-1,2,4-triazol-5-amine

Nom du produit:1-methyl-3-(trifluoromethyl)-1H-1,2,4-triazol-5-amine

IUPAC Name:1-methyl-3-(trifluoromethyl)-1H-1,2,4-triazol-5-amine

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM409298-1g	5-6 Weeks	ƅƅœȤ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 80343-16-4 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:80343-16-4; Formule moléculaire:C4H5F3N4; Point de fusion:-; Code SMILES:CN1N=C(N=C1N)C(F)(F)F; Densité:

: Numéro de catalogue:CM409298; Poids moléculaire:166.11; Point d'ébullition:; N° Mdl:; Stockage:

: Fluorinated Compounds; Fluorine is the most electronegative element in the periodic table, and the fluorine atom has a small atomic radius, so fluorine-containing organic compounds have many wonderful properties. For example, the introduction of fluorine atoms or fluorine-containing groups into drug molecules can improve the permeability to cell membranes, metabolic stability and bioavailability; in addition, the introduction of fluorine atoms will improve the lipid solubility of the compound and promote its absorption in the body. The speed of delivery changes the physiological effect. In the field of medicinal chemistry, the introduction of fluorine atoms into organic molecules is an important direction for the development of new anticancer drugs, antitumor drugs, antiviral agents, anti-inflammatory drugs, and central nervous system drugs.

: Triazoles; Triazole refers to a heterocyclic compound with the molecular formula C2H3N3, which has a five-membered ring consisting of two carbon atoms and three nitrogen atoms. Neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease already affect many people around the world, and these numbers are increasing rapidly. Treatment for these disorders is often aimed at relieving symptoms and has no cure. Research on new molecules is underway, and heterocyclic compounds have important pharmacological implications. Triazoles and tetrazoles are emerging as new molecules in this field.